SUBSCRIBE

Breaking News on Biopharmaceutical Development & Manufacturing

Antibody, drug. Drug, antibody. Just like that.

Antibody-drug conjugates

Antibody-drug conjugates are one of the most active areas of biopharma research and investment for developers and contract manufacturing firms alike. In this section we will collate our coverage of this exciting market.

Catalent sells rights to ADC candidate and gains development contract

12-Oct-2016 - Catalent will continue to develop and manufacture a non-Hodgkin’s Lymphoma antibody-drug conjugate (ADC) for Triphase Accelerator Corporation after licensing out the candidate.

Piramal: $53m Ash Stevens addition ‘synergistic’ with ADC business

18-Aug-2016 - The acquisition of Ash Stevens and a US high potent API facility will bolster Piramal’s antibody-drug conjugate offerings, the Indian CDMO says.

BIO 2016

Technology, not capacity, driving Catalent’s biologics strategy

14-Jun-2016 - Differentiated technologies buoyed by the recent $600m conjugation deal with Roche is driving Catalent’s biologics business, the firm told Biopharma-Reporter at BIO.

AbbVie adds stem cell-based ADC in $5.8bn Stemcentrx acquisition

29-Apr-2016 - AbbVie has added the late-stage antibody-drug conjugate (ADC) Rova-T to its pipeline through the $5.8bn acquisition of Stemcentrx.

Biotrinity 2016

Partnerships leading the way for Biopharma's immuno-oncology pipeline

27-Apr-2016 - Three deals in the last week signal AbbVie’s strategy in immuno-oncology but are just the latest examples of Big Biopharma’s trend for clinical partnerships.

BioCellChallenge granted US patent for antibody delivery tech

20-Apr-2016 - Triazamacrocyclic lipid complexes increase the efficiency of antibody-drug conjugates (ADCs) by delivering the payload right into the heart of a cancer cell, says BioCellChallenge.

Pfizer hits up four biotechs in $46m R&D collaboration strategy

19-Jan-2016 - Pfizer has invested $46m in separate collaborations with four R&D companies specialising in developing ADCs, immuno-oncology candidates and gene-therapies.

Pfizer hails CAB tech in ADC licensing deal with Bioatla

08-Dec-2015 - Pfizer and Bioatla have licensed each other’s technology platforms to develop ADCs with Conditionally Active Biologic (CAB) antibodies as the payload delivery vehicles.

Abzena to buy TCRS in latest boost to its ADC offering

24-Nov-2015 - Abzena is set to buy The Chemistry Research Solution (TCRS) in a deal one analyst says shows the firm’s intentions to dominate the bio-conjugation space.

CPhI Worldwide 2015

Profile of a CEO: Piramal Chief shares M&A plans

21-Oct-2015 - Piramal chief executive Vivek Sharma won last week’s CPhI award for the pharma industry’s CEO of the year. Outsourcing-Pharma.com spoke to Sharma about his plans for the CDMO the day...

Althea building site for highly active bioproduction and ADCs

16-Oct-2015 - CDMO Ajinomoto Althea is opening a new facility to offer outsourced ADC (antibody drug conjugate) and HPAPI (highly potent active pharmaceutical ingredient) manufacturing, the Californian company has announced.

ADC Bio to build Welsh manufacturing site on back of antibody-drug demand

09-Oct-2015 - UK-based processing tech provider ADC Biotechnology will build a $10m plant for the GMP manufacture of antibody-drug conjugates (ADCs).

Roche's haemophilia A bispecific antibody granted USFDA breakthrough status

08-Sep-2015 - A bispecific antibody developed by Roche subsidiary Chugai has been granted Breakthrough Therapy Designation by the US FDA for the treatment of haemophilia A.

European firms form JV for protein delivery polymers

11-Aug-2015 - French firm MedinCell and Dutch company Corbion have formed a JV to produce polymers for unusual drug delivery of large and small molecule drugs.

Novasep expanding conjugation capability to help simplify ADC supply chain

30-Jun-2015 - Novasep is investing €10m ($11m) in a bio-conjugation plant it says will offer drugmakers a more complete antibody-drug conjugation (ADC) service.

Bubble delivery can rescue failing drug candidates, says Oxford team

02-Jun-2015 - University of Oxford scientists are saving undeliverable drugs by placing them in gas bubbles for better bioavailability and fewer side effects.

Crescendo awarded grant to validate antibody fragment-drug conjugates

29-May-2015 - Innovate UK has awarded Crescendo Biologics a grant to fund development of drugs combining cytotoxic small molecule payloads with antibody fragments known as Humabodies.

WuXi adding ADC tech to services in Ambrx acquisition

22-May-2015 - A consortium including WuXi PharmaTech has agreed to acquire biotech client Ambrx for its antibody-drug conjugate (ADC) conjugation technology.

Cancer-hunting shark proteins are the future of drug conjugation, says Almac

19-May-2015 - Almac is coupling tiny shark proteins to a cancer-killing warhead to develop an oncology drug, saying their small size makes for easy conjugation. 

$20m Takeda-ImmunoGen licensing deal for cancer ADCs

25-Mar-2015 - Takeda has licensed technology from ImmunoGen to make two antibody drug conjugates (ADCs) targeting cancer.

Piramal acquires Kentucky-based CDMO for $30m

20-Jan-2015 - India-based CMO Piramal has acquired US-based sterile injectable CDMO (contract development and manufacturing organization) Coldstream Laboratories for $30.65m.

Nicotine vaccine could vanish cigarette habits in a puff of smoke

16-Jan-2015 - The Scripps Research Institute has created a nicotine conjugate vaccine with a technique it says could also treat cocaine, heroin, and methamphetamine addiction.

Sanofi selects B-I to manufacture growing monoclonal antibody portfolio

16-Jan-2015 - Sanofi has selected Boehringer-Ingelheim to manufacture monoclonal antibodies in an agreement that extends to the French drugmaker's partner Regeneron.

Probodies perfect! CytomX raises $20m funding led by Pfizer

07-Jan-2015 - The $20m funding led by Pfizer Venture Investments will help advance a platform to make Probodies which CytomX says offers more precise tumour targeting than antibodies.

AbbVie buys small molecule API plant to support ADC manufacture in Singapore

25-Nov-2014 - An API facility in Singapore acquired by AbbVie on the site where it is building a $320m biologics plant will support the firm's antibody-drug conjugate (ADC) pipeline.

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...